Tag: Penumbra

Penumbra, Inc. Schedules Third Quarter 2018 Earnings Release and Conference Call for November 5, 2018

ALAMEDA, Calif., Oct. 15, 2018 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the third quarter 2018 after market close on Monday, November 5, 2018 at 5:00 PM Eastern Time. A press release with third quarter 2018 financial results will be issued after market […]

PENUMBRA LAUNCHES LATEST ADVANCEMENTS IN STROKE THROMBECTOMY ASPIRATION TECHNOLOGY

ALAMEDA, Calif. – September 4, 2018 – Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced U.S. commercial availability of the Penumbra System’s most advanced technology: Penumbra JET 7 and Penumbra JET D Reperfusion Catheters powered by the Penumbra ENGINE aspiration source. All are part […]

Penumbra, Inc. Schedules First Quarter 2018 Earnings Release and Conference Call for May 8, 2018

ALAMEDA, Calif., April 18, 2018 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2018 after market close on Tuesday, May 8, 2018 at 4:30 PM Eastern Time. A press release with first quarter 2018 financial results will be issued after market […]

INDEPENDENT STUDY REAFFIRMS PENUMBRA ASPIRATION AS FRONTLINE THROMBECTOMY APPROACH FOR ACUTE ISCHEMIC STROKE

Results of COMPASS Trial Presented at International Stroke Conference LOS ANGELES – Jan. 25, 2018 – Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced the presentation of the results of the COMPASS Trial, an independent, prospective, multi-center randomized trial that showed the use of […]

ASPIRATION FIRST APPROACH WITH PENUMBRA SYSTEM DEMONSTRATES FAVORABLE OUTCOMES FOR ACUTE ISCHEMIC STROKE

Results of the PROMISE Study Presented at International Stroke Conference LOS ANGELES – January 25, 2018 – Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced results of the company-sponsored PROMISE Study, demonstrating real-world safety and efficacy of the Penumbra System with ACE™68 and ACE™64 […]

Penumbra, Inc. Reports Third Quarter 2017 Financial Results

ALAMEDA, Calif., Nov. 7, 2017 /PRNewswire/ — Penumbra, Inc.(NYSE: PEN), a global healthcare company focused on interventional therapies, today reported financial results for the third quarter ended September 30, 2017. Revenue of $83.9 million in the third quarter of 2017, an increase of 24.9%, or 24.1% in constant currency1, over the third quarter of 2016. […]

Surmodics Reports Fourth Quarter Fiscal 2017 Results and Provides Fiscal 2018 Guidance

EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2017 fourth quarter, ended September 30, 2017 and financial outlook for fiscal 2018. Recent Highlights First Patient Enrolled in TRANSCEND Pivotal Clinical […]

Penumbra, Inc. Announces Participation at Upcoming Investor Conferences

ALAMEDA, Calif., Aug. 24, 2017 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the following upcoming investor conferences: Event:         Wells Fargo 2017 Healthcare Conference Location:    Boston, MA at the Westin Boston Waterfront Date:           Thursday, September 7, 2017 Time:          1:40pm ET / 10:40am PT Event:         Morgan […]